AE Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

AE Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$818K	Sell	24,136 -10,277	-30%	-$342K	﹤0.01%	992
2026 Q1	$1.04M	Sell	34,413 -39,614	-54%	-$1.27M	0.01%	830
2025 Q4	$2.31M	Sell	74,027 -52,672	-42%	-$1.3M	0.01%	569
2025 Q3	$2.56M	Sell	126,699 -1,435	-1%	-$25.2K	0.02%	502
2025 Q2	$2.15M	Sell	128,134 -44,852	-26%	-$724K	0.02%	521
2025 Q1	$2.66M	Sell	172,986 -3,888	-2%	-$69.5K	0.02%	461
2024 Q4	$3.9M	Sell	176,874 -18,473	-9%	-$336K	0.03%	389
2024 Q3	$3.52M	Sell	195,347 -3,461	-2%	-$60.6K	0.03%	408
2024 Q2	$3.23M	Buy	198,808 +44,718	+29%	+$689K	0.03%	422
2024 Q1	$2.17M	Sell	154,090 -68,401	-31%	-$862K	0.02%	474
2023 Q4	$2.65M	Buy	+222,491	New	+$2.08M	0.01%	810

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

AE Wealth Management's TEVA Position: Q2 2026 in Review

AE Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 30% in Q2 2026, selling an estimated $342K and leaving 24,136 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #992.

AE Wealth Management first reported a position in TEVA in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.9M in Q4 2024. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

AE Wealth Management held 24,136 shares of Teva Pharmaceuticals worth $818K as of Q2 2026.
AE Wealth Management sold 10,277 Teva Pharmaceuticals shares in Q2 2026, an estimated $342K.
Teva Pharmaceuticals made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #992 holding.
AE Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
AE Wealth Management's Teva Pharmaceuticals position peaked at $3.9M in Q4 2024.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.